The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study

Author(s):
Arzu AcarArzu Acar1, Elvan ErhanElvan Erhan1, M. Nuri DenizM. Nuri Deniz1,*, Gulden UgurGulden Ugur1
1Department of Anaesthesiology and Reanimation, School of Medicine, Ege University, [email protected], Turkey

Anesthesiology and Pain Medicine:Vol. 2, issue 3; 119-122
Published online:Jan 01, 2013
Article type:Research Article
Received:Aug 18, 2012
Accepted:Oct 10, 2012
How to Cite:Acar A, Erhan E, Nuri Deniz M, Ugur G. The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study. Anesth Pain Med. 2013;2(3):. doi: https://doi.org/10.5812/aapm.7790

Abstract

Background:

To alleviate stinging pain in the skin entry area and visceral discomfort in patients who are undergoing ESWL.

Objectives:

This study was designed to investigate the effectiveness of the EMLA cream in combination with remifentanil patient-controlled analgesia (PCA) in patients undergoing ESWL treatment.

Patients and Methods:

Sixty patients were divided into two double-blind randomized groups. Those in the first group were administered 3-5mm of EMLA 5% cream on a marked area; the second group received, as a placebo, a cream with no analgesic effect in the same amount. All patients were administered a remifentanil bolus with a PCA device. Arterial blood pressure, oxygen saturation, and respiratory rate were recorded throughout the procedure; postoperative side effects, agitation, and respiratory depression were measured after. Visual Analogue Scale (VAS) scores were taken preoperatively, perioperatively, directly postoperatively, and 60 minutes subsequent to finishing the procedure.

Results:

There were no statistically significant differences in the frequency of PCA demands and delivered boluses or among perioperative VAS. No significant side effects were noted. Patient satisfaction was recorded high in both groups.

Conclusions:

EMLA cream offered no advantage over the placebo cream in patients undergoing ESWL with remifentanil PCA.

Full Text

Full text is available in PDF

Crossmark
Crossmark
Checking
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles